• Trilaurin (Glycerol Tridodecanoate): Biocatalytic Innovation

  2026-07-25

  Discover how Trilaurin (Glycerol Tridodecanoate) is revolutionizing biocatalytic synthesis and multifunctional lipid excipient roles. This article uniquely bridges mechanistic insight, comparative innovation, and practical assay impact in pharmaceutical and industrial biotechnology.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-07-24

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve labile phosphorylation states during sample processing, ensuring high-fidelity data in phosphoproteomic and signaling pathway analyses. Its robust inhibition spectrum and operational flexibility outperform conventional approaches in Western blotting, immunoprecipitation, and kinase assays.

• Ruxolitinib Phosphate Induces Mitochondrial Dysfunction in A

  2026-07-24

  A recent study delineates how Ruxolitinib phosphate (INCB018424), a selective JAK1/2 inhibitor, triggers apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma by inhibiting DRP1-driven mitochondrial fission. These findings provide mechanistic insight into JAK/STAT pathway modulation as a therapeutic strategy for aggressive thyroid cancers.

• Staurosporine: Broad-Spectrum Kinase Inhibitor for Cancer Re

  2026-07-23

  Staurosporine stands as the gold standard broad-spectrum serine/threonine protein kinase inhibitor, empowering researchers to dissect kinase-driven apoptosis and metastatic signaling in cancer models. Its nanomolar potency, broad target profile, and reliable performance—backed by APExBIO’s validated quality—make it indispensable for studies on cell motility, invasion, and anti-angiogenic therapy development.

• Rapakinin-Induced Vasorelaxation in Hypertension: NO-Indepen

  2026-07-23

  This study identifies rapakinin, a rapeseed-derived tripeptide, as an antihypertensive agent that induces vasorelaxation in spontaneously hypertensive rats via prostaglandin I2 (PGI2) IP and downstream CCK1 receptors, rather than through nitric oxide (NO) signaling. The findings challenge conventional assumptions about peptide-based vascular tone modulation and provide new insights for cardiovascular disease models.

• Parathyroid hormone (1-34) (human): Applied Protocols in Bon

  2026-07-22

  Parathyroid hormone (1-34) (human) empowers high-fidelity modeling of calcium homeostasis, bone formation, and advanced kidney assembloid workflows. This guide demystifies its integration into experimental pipelines, with actionable troubleshooting, protocol parameters, and cross-study insights for translational research.

• Dantrolene Sodium Salt: Beyond RyR Antagonism in Precision D

  2026-07-22

  Explore how Dantrolene sodium salt, a powerful ryanodine receptor antagonist, enables next-generation control of DNA repair outcomes in genome editing and disease modeling. Discover mechanistic insights, protocol guidance, and the latest repurposing evidence that set this compound apart.

• EDI3 Inhibition Reduces Viability in HER2-Resistant Breast C

  2026-07-21

  Keller et al. identify the glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells resistant to HER2-targeted therapies. By demonstrating that EDI3 inhibition reduces cell viability and tumor growth, the study proposes a novel therapeutic target for overcoming resistance in this aggressive breast cancer subtype.

• Tamoxifen Beyond Cancer: Mechanisms, Emerging Uses, and Prot

  2026-07-21

  Explore Tamoxifen's depth as a selective estrogen receptor modulator, from its nuanced mechanisms to advanced research applications and cutting-edge protocol guidance. Discover how this cornerstone compound propels innovation in breast cancer and gene editing studies.

• RITA (NSC 652287): Applied Protocols in Cancer Biology

  2026-07-20

  RITA (NSC 652287) empowers cancer researchers with a precision tool for dissecting p53-mediated responses, offering nanomolar potency and selective cytotoxicity in renal carcinoma models. This article distills advanced workflows, troubleshooting strategies, and insights from recent in vitro methodology breakthroughs to maximize RITA's impact in translational cancer studies.

• Canagliflozin as a Mitochondrial Modulator: Beyond SGLT2 Inh

  2026-07-20

  Explore Canagliflozin’s dual role as a potent SGLT2 inhibitor and mitochondrial modulator in advanced diabetes research. This article uncovers novel insights into renal glucose reabsorption inhibition and metabolic remodeling, offering a fresh perspective for assay design.

• Ziprasidone HCl Targets GOT1 to Reprogram Pancreatic Cancer

  2026-07-19

  The referenced study identifies Ziprasidone HCl as a novel non-competitive inhibitor of GOT1, disrupting glutamine metabolism and suppressing proliferation in pancreatic ductal adenocarcinoma (PDAC) models. These findings offer a mechanistic basis for further exploration of antipsychotic agents in cancer metabolism research.

• Targeting Aurora A in Cancer: MK-8745 for Translational Inno

  2026-07-18

  This thought-leadership article examines the mechanistic rationale and translational trajectory for targeting Aurora kinase A in high-risk cancers, with a focus on the potent and selective inhibitor MK-8745. Integrating findings from recent retinoblastoma studies and referencing advanced workflows, the piece offers strategic guidance for researchers aiming to leverage MK-8745 in preclinical and translational oncology models. Protocol parameters and clinical perspectives are included to guide adoption and innovation.

• SIRT1/2 Inhibitor IV (Cambinol): Mechanisms & Research Bench

  2026-07-17

  SIRT1/2 Inhibitor IV (cambinol) is a cell-permeable small molecule that selectively inhibits the NAD-dependent deacetylases SIRT1 and SIRT2, enabling precise modulation of acetylation pathways. Cambinol displays efficacy in both cancer and CNS injury models, including induction of protein hyperacetylation and suppression of tumor growth. This article reviews its mechanism, benchmarked evidence, and workflow parameters for advanced research contexts.

• Phytol for RXR Activation: Bridging Mechanisms and Translati

  2026-07-17

  Explore the strategic potential of Phytol as a nuclear hormone receptor activator, integrating recent mechanistic insights with workflow guidance for translational researchers. This piece advances the conversation beyond standard assay protocols—connecting RXR biology, advanced nanomaterial design, and the future of cross-domain translational workflows.

449 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page